Abstract:Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is often already advanced or metastatic, resulting in poor treatment outcomes. Treatment of NSCLC mainly relies on surgery, radiation and chemotherapy, but the survival rate has not increased significantly in the past decade. Therefore, finding appropriate treatment methods is necessary and crucial. Radiotherapy (RT) is a frequently employed approach for tumor treatment and serves as the primary local treatment for NSCLC. However, it often results in a poor prognosis and severe side effects when administered at high-dose irradiation. Existing literature suggests that RT may trigger the expression of nuclear factor kappa B (NF-ΚB), potentially compromising its therapeutic efficacy. Consequently, the question remains: Can targeting NF-ΚB signaling enhance the sensitivity of RT in NSCLC Furthermore, studies have indicated that elevated levels of CXCR5 in NSCLC contribute to tumor growth. CXCR5 is situated upstream of the NF-ΚB pathway. As a result, it becomes imperative and indispensable to develop strategies targeting the CXCL13/CXCR5/NF-ΚB signaling axis to counteract NSCLC growth. Lenvatinib is a multi-kinase inhibitor targeted drug. It has been proven to inhibit VEGFR1-3, FGFR1-4 and PDGFR, inhibiting tumor growth. Lenvatinib has received clinical approval from the US FDA for the treatment of advanced hepatocellular carcinoma (HCC) and has been shown to inhibit NF-ΚB expression in HCC. However, the potential radiation-sensitizing mechanism of Lenvatinib in lung cancer remains unexplored. This study is dedicated to investigating the effects and molecular mechanisms of combining Lenvatinib with radiotherapy in NSCLC. Our results suggest that lenvatinib may enhance the sensitivity of NSCLC to RT. Furthermore, evidence from both the intrinsic and extrinsic apoptosis pathways (Caspase-3/Caspase-8/Caspase-9) and TUNEL experiments supports the idea that the combined treatment of lenvatinib with RT induces a more pronounced apoptotic response compared to individual treatments. Additionally, silencing CXCR5 in NSCLC also appears to enhance its responsiveness to RT. In our western blot (p-ATM, p-CHK2), flow cytometry (p-ATM), we showed that the combination of lenvatinib and RT may effective induce DNA damage. Our in vivo data demonstrates that the combination of Lenvatinib and RT exhibits superior tumor growth inhibition. Immunohistochemistry (IHC) staining of tumor tissue also revealed an upregulation of apoptosis-related proteins and the downregulation of CXCL13/CXCR5/NF-ΚB related proteins. In conclusion, our findings suggest that Lenvatinib can serve as a radiosensitizer, enhancing the sensitivity of NSCLC patients to radiotherapy by targeting the CXCL13/CXCR5/NF-ΚB signaling pathway. Citation Format: Tsai-Lan Liao, I-Tsang Chiang, Bo-Han Huang, Fei-Ting Hsu, Ming-Hsien Chan. Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 695.

TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy

Icotinib Hydrochloride Enhances Chemo- And Radiosensitivity By Inhibiting Egfr Signaling And Attenuating Rad51 Expression And Function In Hela S3 Cells

Abstract 1125: TNIK induced chemoradiation resistance in small cell lung cancer

Abstract 2818: Investigating the role of TNIK in the pathogenesis of lung squamous cell carcinoma

Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression

Abstract 6799: The impact of targeting TRAF2 and NCK-interacting protein kinase on anti-tumor effect and tumor immune environment in cMYC-high small cell lung cancer

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer

Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma

Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin

Abstract 695: Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade

S6K1 Controls DNA Damage Signaling Modulated by the MRN Complex to Induce Radioresistance in Lung Cancer

KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials

Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells

Single-cell transcriptomics reveals that tumor-infiltrating natural killer cells are activated by localized ablative immunotherapy and share anti-tumor signatures induced by immune checkpoint inhibitors

Topoisomerase I Inhibitors in the Combined Modality Therapy of Lung Cancer

Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence

Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer

P2.05-005 Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance: Topic: Biology